Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial Officer
Tessa Therapeutics today announced the appointment of Wilson W. Cheung as its chief financial officer…
Continue ReadingTessa Therapeutics today announced the appointment of Wilson W. Cheung as its chief financial officer…
Continue ReadingTessa Therapeutics today announced clinical data from the pilot stage of the ongoing Phase 2…
Continue ReadingTessa Therapeutics today announced clinical data from an ongoing Phase 1 study (NCT04288726) of TT11X,…
Continue ReadingTessa Therapeutics today announced that data from its ongoing autologous and allogeneic cell therapy studies…
Continue ReadingTessa Therapeutics today announced a collaboration agreement with the Agency for Science Technology and Research’s…
Continue ReadingTessa Therapeutics today announced early clinical results for an allogeneic CD30-CAR EBVST therapy (TT11X), being…
Continue ReadingTessa Therapeutics today announced that early clinical data from a Phase 1 dose-escalation study of…
Continue ReadingTessa Therapeutics today announced enrollment of 12 patient Pilot cohort of its Phase 2 trial…
Continue ReadingTessa Therapeutics today announced the successful completion of dosing of the first patient cohort (n=3)…
Continue ReadingTessa Therapeutics today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME)…
Continue Reading